Tachykinin NK2 receptor antagonists. A patent review (2006 - 2010)

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 1, 2012, Pages 57-77

  Altamura, Maria ^a  

^a Menarini Ricerche SpA   (Italy)

Author keywords

asthma; atopic dermatitis; depression; infant colic; inflammation; irritable bowel syndrome; neurokinin A; NK2 receptor antagonists; tachykinins

Indexed keywords

AVE 5883; CARBAZOLE DERIVATIVE; CS 003; DNK 333; ESCITALOPRAM; IBODUTANT; M 274773; NALPHA (TERT BUTYLCARBAMOYL)GLUTAMINYLTRYPTOPHYL ALPHA AZAPHENYLALANINE 2 BENZYLOXYETHYLAMIDE; NEPADUTANT; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR ANTAGONIST; NEUROKININ 3 RECEPTOR ANTAGONIST; PAROXETINE; PIPERIDINE DERIVATIVE; PREDNISOLONE; QUINOLINE DERIVATIVE; SAREDUTANT; SSR 241586; SUBSTANCE P ANTAGONIST; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; WO 07063086; WO 07088181; ZM 274773;

ANXIETY DISORDER; ASTHMA; ATOPIC DERMATITIS; ATTENTION DEFICIT DISORDER; BINDING AFFINITY; BRONCHOSPASM; CLINICAL TRIAL; COLIC; DEPRESSION; DRUG BIOAVAILABILITY; DRUG STRUCTURE; DYSPEPSIA; ECZEMA; HUMAN; IC 50; ILEUS; INFLAMMATION; INSECT BITE; IRRITABLE COLON; MENINGITIS; NONHUMAN; OVERACTIVE BLADDER; PATENT; PEDICULOSIS; PHOBIA; POSTTRAUMATIC STRESS DISORDER; PRURITUS; PSORIASIS; PSYCHOSIS; REVIEW; SCABIES; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; STROKE; T CELL LYMPHOMA; TRAUMATIC BRAIN INJURY; TREATMENT INDICATION; URINE INCONTINENCE; URTICARIA;

ANIMALS; DRUG DESIGN; FEMALE; FEMALE UROGENITAL DISEASES; GASTROINTESTINAL DISEASES; HUMANS; INFLAMMATION; MALE; MALE UROGENITAL DISEASES; PATENTS AS TOPIC; RECEPTORS, NEUROKININ-2; TACHYKININS;

EID: 84855497732     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.645537     Document Type: Review

References (98)

1. Maggi CA, Patacchini R, Rovero P, Giachetti A. Tachykinin receptors and tachykinin receptor antagonists. J Auton Pharmacol 1993;13:23-93 (Pubitemid 23054476)
2. Pennefather JN, Lecci A, Luz Candenas M, et al. Tachykinin and tachykinin receptors: a growing family. Life Sci 2004;74:1445-63
3. Evangelista S, Patacchini R, Maggi CA. Role of peripheral tachykinin receptors in neurogenic inflammation of the respiratory, genitourinary and gastrointestinal systems. Curr Med Chem Anti Inflamm Anti Allergy Agents 2003;2:157-74
4. Quartara L, Altamura M, Evangelista S, Maggi CA. Tachykinin receptor antagonists in clinical trials. Expert Opin Invest Drugs 2009;18:1843-64
5. Bensaid M, Faucheux BA, Hirsch E, et al. Expression of tachykinin NK2 receptor mRNA in human brain. Neurosci Lett 2001;303:25-8 (Pubitemid 32285459)
6. Saffroy M, Torrens Y, Glowinski J, et al. Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: comparison with NK1 and NK3 binding sites. Neuroscience 2003;116:761-73 (Pubitemid 36160572)
7. Nagano M, Oishi T, Suzuki H. Distribution and pharmacological characterization of primate NK2 tachykinin receptor in the central nervous system of the rhesus monkey.Neurosci Lett 2011;503:23-6
8. Albert JS. Neurokinin antagonists and their potential role in treating depression and other stress disorders. Expert Opin Ther Patents 2004;14:1421-33 (Pubitemid 39378298)
9. Steinberg R, Alonso R, Griebel G, et al. Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J Pharmacol Exp Ther 2001;299:449-58 (Pubitemid 32979655)
10. Louis C, Stemmelin J, Boulay D, et al. Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models. Pharmacol Biochem Behav 2008;89:36-45
11. Le Fur G. Sanofi-aventis Information Meeting; February 16 2004
12. Phase III clinical trials reported in the ClinicalTrials.gov database. Available from: http://www.clinicaltrials.gov [Last accessed 15 September 2011]
13. Sanofi-aventis Press Release, July 31, 2008
14. Sanofi-aventis Press Release, April 29, 2009
15. Shimizu Y, Matsuyama H, Shiina T, et al. Tachykinin and their functions in the gastrointestinal tract. Cell Mol Life Sci 2008;65:295-311 (Pubitemid 351161478)
16. Jaafari N, Khomitch-Baud A, Christen MO, et al. Distribution pattern of tachykinin NK2 receptors in human colon: involvement in the regulation of intestinal motility. J Comp Neurol 2007;503:381-91 (Pubitemid 46982478)
17. Maggi CA, Patacchini R, Santicioli P, et al. Human isolated ileum: motor responses of the circular muscle to electrical field stimulation and exogenous neuropeptides. Naunyn Schmiedebergs Arch Pharmacol 1990;341:256-61 (Pubitemid 20102217)
18. Giuliani S, Barbanti G, Turini D, et al. NK2 tachykinin receptors and contraction of circular muscle of the human colon: characterization of the NK2 receptor subtype. Eur J Pharmacol 1991;203:365-70
19. Giuliani S, Guelfi M, Toulouse M, et al. Effect of a tachykinin NK2 receptor antagonist, nepadutant, on cardiovascular and gastrointestinal function in rats and dogs. Eur J Pharmacol 2001;415:61-71 (Pubitemid 32197620)
20. Lecci A, Capriati A, Maggi CA. Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome. Br J Pharmacol 2004;141:1249-63 (Pubitemid 38638814)
21. Toulouse M, Coelho AM, Fioramonti J. Role of tachykinin NK2 receptors in normal and altered rectal sensitivity in rats. Br J Pharmacol 2000;129:193-9 (Pubitemid 30072687)
22. Lecci A, Capriati A, Altamura M, Maggi CA. Tachykinin and tachykinin receptors in the gut, with special reference to NK2 receptors in human. Auton Neurosci 2006;126-7:232-49 (Pubitemid 43833351)
23. Lordal M, Navalesi G, Theodorsson E, et al. A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine. Br J Pharmacol 2001;134:215-23 (Pubitemid 32835485)
24. Menarini Group. Study NCT00761007. Double-blind, randomised, placebo-controlled, parallel group study to evaluate the effect of a 4-week treatment with oral doses of ibodutant (code: MEN15596) in Irritable Bowel Syndrome (IBS). Available from: http:// www.clinicaltrials.gov [Last accessed 16 September 2011]
25. Menarini Group. Study NCT01303224. Double-blind, randomised, placebo-controlled, parallel-group Phase II study to evaluate the effect of oral ibodutant in Irritable Bowel Syndrome with Diarrhoea (IBS-D). Available from: http://www.clinicaltrials. gov [Last accessed 16 September 2011]
26. Zakko S, Barton G, Weber E, et al. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2011;33:1311-21
27. Rogers DF. Tachykinin receptor antagonists for asthma and COPD. Expert Opin Ther Patents 2001;11:1097-121 (Pubitemid 32633392)
28. Altamura M, Manzini S, Lecci A. Tachykinin receptors in chronic inflammatory lower airway diseases. Expert Opin Ther Patents 2007;17:1241-73 (Pubitemid 350104052)
29. Ramalho R, Soares R, Couto N, Moreira A. Tachykinin receptors antagonism for asthma: a systematic review. BMC Pulm Med 2011;11:41
30. Kraan J, Vink-Klooster H, Postma DS. The NK-2 receptor antagonist SR 48968C does not improve adenosine hyperresponsiveness and airway obstruction in allergic asthma. Clin Exp Allergy 2001;31:274-8 (Pubitemid 32232996)
31. Boot JD, de Haas S, Tarasevych S, et al. Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma. Am J Respir Crit Care Med 2007;175:450-7 (Pubitemid 46354248)
32. Candenas L, Lecci A, Pinto FM, et al. Tachykinins and tachykinin receptors: effects in the genitourinary tract. Life Sci 2005;7:835-62 (Pubitemid 39601890)
33. Malherbe P, Ballard TM, Ratni H. Tachykinin neurokinin 3 receptor antagonists: a patent review (2005 - 2010). Expert Opin Ther Patents 2011;21:637-55
34. Huang SC, Korlipara VL. Neurokinin-1 receptor antagonists: a comprehensive patent survey. Expert Opin Ther Patents 2010;20:1019-45
35. AstraZeneca AB. Novel treatment of gastrointestinal disorders. WO06062478; 2006
36. AstraZeneca AB. New azetidine compounds. WO04110344;2004
37. AstraZeneca AB. Novel crystalline form of 3,5-dibromo-N-[(2S)-2-(-4- fluorophenyl)-4-(3-morpholin-4- ylazetidin-1-yl)butyl]-Nmethylbenzamide, modification A. WO07043939;2007
38. AstraZeneca AB. Novel crystalline form of 3,5-dibromo-N-[(2S)-2-(-4- fluorophenyl)-4-(3-morpholin-4- ylazetidin-1-yl)butyl]-Nmethylbenzamide, modification B. WO07043938;2007
39. AstraZeneca AB. Use of a neurokinin-2 receptor antagonist for treating or preventing detrusor overactivity. WO06121389;2006
40. AstraZeneca AB. Compounds and method for the treatment of overactive bladder. WO03037889;2003
41. Abdel-Karim AM, Barthlow HG, Bialecki RA, Elhilali MM. Effects of M274773, a neurokinin-2 receptor antagonist, on bladder function in chronically spinalized rats. J Urol 2005;174:1488-92 (Pubitemid 41318771)
42. AstraZeneca AB. New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases. WO06137790; 2006
43. AstraZeneca AB. New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases. WO06137791; 2006
44. AstraZeneca AB. Novel azetidine compounds useful in the treatment of functional gastrointestinal disorders, IBS and functional dyspepsia. WO07037742; 2007
45. AstraZeneca AB. Novel azetidine compounds useful in the treatment of functional gastrointestinal disorders, IBS and functional dyspepsia. WO07037743; 2007
46. AstraZeneca AB. 1-[(4-[benzoyl(methyl) amino]-3-(phenyl)butyl]azetidine derivatives for the treatment of gastrointestinal disorders 1. WO07136324;2007
47. AstraZeneca AB. 1-[(4-[benzoyl(methyl) amino]-3-(phenyl)butyl]azetidine derivatives for the treatment of gastrointestinal disorders 2. WO07136325;2007
48. AstraZeneca AB. New compounds 302. WO07136326;2007
49. AstraZeneca AB. Azetidin-azabicyclo [3.2.1]octan derivatives that are neurokinin (NK) receptor antagonists and their use. WO08076041;2008
50. AstraZeneca AB. Azetidinpiperazine derivatives that are neurokinin (NK) receptor antagonists and their use. WO08076042;2008
51. Albireo AB. A fumarate salt of 3-bromo- N-{(2S)-2-(4-fluorophenyl)-4-[3- (4- acetylpiperazin-l-yl)azetidin-1-yl]butyl}- N-methyl-5-(trifluoromethyl) benzamide for the treatment of gastrointestinal disorders. WO08118091;2008
52. Albireo AB. Maleate salt of 3-bromo-N- {(2S)-2-(4-fluorophenyl)-4-[3-(4- acetylpiperazin-1-yl)azetidin-1-yl]butyl}- N-methyl-5-(trifluoromethyl)benzamide for the treatment of gastrointestinal disorders. WO08118092;2008
53. Albireo Pharma, Co. website. Available from: http://www.albireopharma.com [Last accessed 6 October 2011]
54. Merck Sharp & Dohme Ltd. Quinoline derivatives as neurokinin receptor antagonists. WO06013393;2006
55. Merck Sharp & Dohme Ltd. Quinoline derivatives as neurokinin receptor antagonists. WO06013394;2006
56. Quartara L, Altamura M. Tachykinin receptors antagonists: from research to clinic. Curr Drug Targets 2006;7:975-92 (Pubitemid 44227581)
57. Merck Sharp & Dohme Ltd. Quinoline derivatives as neurokinin receptor antagonists. WO06120478;2006
58. Merck Sharp & Dohme Ltd. Quinoline derivatives as neurokinin receptor antagonists. WO07012900;2007
59. Sanofi-Aventis. 4-arylmorpholin-3-one derivatives, preparation and therapeutic use thereof. WO06021654;2006
60. Emonds-Alt X, Advenier C, Cognon C, et al. Biochemical and pharmacological activities of SR 144190, a new potent non-peptide tachykinin NK2 receptor antagonist. Neuropeptides 1997;31:449-58 (Pubitemid 27525137)
61. Takeda Pharmaceutical Co. Ltd. Pyrroloquinoline derivative and use thereof. WO08153027;2008
62. Takeda Pharmaceutical Co. Ltd. Fused quinoline derivative and use thereof. WO05105802;2005
63. Takeda Pharmaceutical Co. Ltd. Dihydropyrroloquinoline derivatives. WO11055810;2011
64. Takeda Pharmaceutical Co. Ltd. Nitrogen-containing heterocyclic compound and use thereof. WO09072643;2009
65. Takeda Pharmaceutical Co. Ltd. Nitrogen-containing heterocyclic compound and use of same. WO10032856;2010
66. Takeda Pharmaceutical Co. Ltd. Quinolone derivative and use thereof. WO09128262;2009
67. F. Hoffmann-La Roche AG. Spiropiperidine derivatives as NK3 antagonists. WO08081012;2008
68. F. Hoffmann-La Roche AG. Pyrrolidine derivatives as NK2 receptor antagonists. WO09153179;2009
69. Solvay Pharmaceuticals GmbH. Novel NK1 and NK2 antagonists. WO07063086;2007
70. Solvay Pharmaceuticals GmbH. Novel dual NK2/NK3-antagonists, pharmaceutical compositions comprising them and processes for their preparations. WO07088181;2007
71. Zentaris GmbH, Solvay Pharmaceutical BV. Novel tetrahydrocarbazole derivatives with improved biological action and improved solubility as ligands for G-protein coupled receptors (GPCRs). WO06005484;2006
72. Aeterna Zentaris GmbH. Novel tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors. WO08132153;2008
73. Daiichi Sankyo Co. Ltd. Amide derivative. WO10106988;2010
74. Tsuchida H, Takahashi S, Nosaka E, et al. Novel triple neurokinin receptor antagonist CS-003 inhibits respiratory disease models in guinea pigs. Eur J Pharmacol 2008;596:153-9
75. United Paragon Associates, Inc. Fertilized egg isolate and use thereof. WO09086634;2009
76. Mount Sinai Hospital, Canada. Study NCT00446719. Safety and Antidepressant Effects of Rellidep in Major Depressive Disorder. Available from: http://www.clinicaltrials.gov [Last accessed 6 September 2011]
77. United Paragon Associates, Inc. Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity. WO11029099;2011
78. Sanofi-Synthelabo. Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same. WO02094821; 2002
79. Sanofi-Aventis. Use of a compound antagonist to the NK2 receptors of a neurokinine for the preparation of drugs useful for preventing and treating sexual dysfunction. WO08110697;2008
80. Sanofi-Aventis. Pharmaceutical composition containing saredutant and a selective inhibitor of serotonin recapture or an inhibitor of serotonin/ norepinephrine recapture in combination. WO08017753; 2008
81. Louis C, Cohen C, Depoortere R, Griebel G. Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat. Neuropsychopharmacology 2006;31:2180-7 (Pubitemid 44413195)
82. Sanofi-Aventis. Study NCT00629551. An Eight-Week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder (COMPASS). Available from: http:// www.clinicaltrials.gov [Last accessed 24 August 2011]
83. Sanofi-Aventis. Study NCT00531622. An Eight-Week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder. Available from: http://www.clinicaltrials.gov [Last accessed 24 August 2011]
84. Laboratori Guidotti (Menarini Group). Pharmaceutical compositions based on NK2 antagonists for pediatric use. WO06045820;2006
85. Menarini Group. Study NCT01258153. Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant Colic (No- Cry). Available from: http://www. clinicaltrials.gov [Last accessed 24 August 2011]
86. Menarini Group. Study NCT01309009. Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant With Colic Not Responding to Conventional Treatment (NoCry-a). Available from: http://www.clinicaltrials.gov [Last accessed 24 August 2011]
87. Tramontana M, Evangelista S, Giuliani S, et al. Influence of tachykinin NK2 receptors on intestinal sensitivity and motility in newborn rats. Neuropeptides 2010;44:269-72
88. Novartis AG. Uses of NK receptor antagonists. WO10097381;2010
89. Novartis Pharmaceuticals. Study NCT01033097. A multicenter, randomized, double-blinded, placebo and positive controlled study to evaluate the anti-pruritic effect, safety and tolerability, systemic and skin exposure, after 2 weeks of treatment with a microemulsion formulation of DNK333 in atopic dermatitis patients. Available from: http://www.clinicaltrials.gov [Last accessed 28 September 2011]
90. Sosei Co. Ltd. Azapeptides for use in therapy. WO08012546; 2008
91. Sosei Co. Ltd. & Neurosolutions Ltd. Azapeptides for treating hyperalgesic pain conditions. WO07020403;2007
92. Higashide Y, Yatabe Y, Arai Y, et al. Pharmacological profiles of a novel tachykinin NK2 receptor antagonist, TAC-363. Yakugaku Zasshi 1996;116:884-91 (Pubitemid 26411842)
93. Higashide Y, Yatabe Y, Arai Y, et al. Effect of a novel tachykinin NK2 receptor antagonist, TAC-363, on bronchoconstriction and airway hyperresponsiveness in guinea pigs. Folia Pharmacol Jpn 1997;109:19-29 (Pubitemid 27044104)
94. Adelaide Research & Innovation Pty Ltd. & James Cook University. Method for reducing inflammatory responses and inflammation. WO08067609;2008
95. Adelaide Research & Innovation Pty Ltd & James Cook University. Method for reducing inflammatory responses and inflammation. WO08067610;2008
96. Adelaide Research & Innovation Pty Ltd. Use of substance P receptor antagonists - for the treatment of intracranial pressure. WO09009829;2009
97. Adelaide Research & Innovation Pty Ltd. Method for preventing and/or treating a disease, condition or state associated with reduced dopaminergic neuron function. WO09109001;2009
98. Amatya B, El-Nour H, Holst M, et al. Expression of tachykinins and their receptors in plaque psoriasis with pruritus. Br J Dermatol 2011;164:1023-9